Tranzyme Pharma (TZYM -65.9%) says a Phase 3 trial of its treatment to speed up gastrointestinal...
Tranzyme Pharma (TZYM -65.9%) says a Phase 3 trial of its treatment to speed up gastrointestinal recovery following abdominal surgery failed to meet its primary endpoint. TZYM, which had planned to test ulimorelin in several additional indications, says it will stop all other activities related to the filing of a new drug application.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs